Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia

7 Feb 2014

Abstract excerpt

Jak2 inhibitors are commonly used in the treatment of patients with myeloproliferative neoplasms, in particular patients with primary myelofibrosis and splenomegaly.[1][1] The currently available Jak2 inhibitors do not distinguish between wild-type (WT) Jak2 and mutant Jak2-V617F. Although a modest

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24510341
DOI: 10.3324/haematol.2013.100016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopeniaPMID 24510341Read ↗

Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in HumansSemantic proximity Read ↗

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaSemantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.Semantic proximity Read ↗

Mouse models of myeloproliferative neoplasms: JAK of all grades.Semantic proximity Read ↗

Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem CellsSemantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasmsSemantic proximity Read ↗

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Hematological phenotypes in GATA2 deficiency syndrome arise from aging, maladaptation to proliferation, and somatic eventsSemantic proximity Read ↗

Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.Semantic proximity Read ↗

Hematological phenotypes in GATA2 deficiency syndrome arise from secondary injuries and maladaptation to proliferationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.